All In Biotech

Drug Trial Radar · NCT02520284

Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis

A Combined Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Induction and Maintenance Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Ulcerative Colitis

Last checked: Nov 20, 2026Latest source record: Apr 10, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 165 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

165

Actual

Start

Sep 2015

Primary completion

Sep 2016

Study completion Nov 2016

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Aug 11, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of this study are as follows: 1) To evaluate the efficacy of andecaliximab to induce endoscopy, rectal bleeding, and stool frequency (EBS) clinical remission at Week 8 (Cohort 1); 2) To evaluate the efficacy of andecaliximab to maintain EBS clinical remission at Week 52 (Cohort 2); and 3) To evaluate the safety and tolerability of andecaliximab. The study will consist of 3 parts: Induction Phase (Cohort 1), Maintenance Phase (Cohort 2), and an optional Extended Treatment Phase.

Conditions

  • Ulcerative Colitis

Interventions

  • AndecaliximabBiological

    Andecaliximab 150 mg administered via SC injection

  • PlaceboBiological

    Placebo matched to andecaliximab administered via SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. For Cohort 1, Percentage of Participants With EBS Clinical Remission at Week 8Time frame: Week 8

Locations

87 sites in 23 countries. Site status is shown where the registry gives one.

  • Site not named

    Dothan, Alabama

  • Site not named

    Wheat Ridge, Colorado

  • Site not named

    Lauderdale Lakes, Florida

  • Site not named

    Miramar, Florida

  • Site not named

    Winter Park, Florida

  • Site not named

    Zephyrhills, Florida

  • Site not named

    Chicago, Illinois

  • Site not named

    Topeka, Kansas

  • Site not named

    Louisville, Kentucky

  • Site not named

    Monroe, Louisiana

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Plymouth, Minnesota

  • Site not named

    St Louis, Missouri

  • Site not named

    Egg Harbor, New Jersey

  • Site not named

    New York, New York

  • Site not named

    Chapel Hill, North Carolina

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Mentor, Ohio

  • Site not named

    Rochester, Ohio

  • Site not named

    Germantown, Tennessee

  • Site not named

    Hermitage, Tennessee

  • Site not named

    Arlington, Texas

  • Site not named

    Baytown, Texas

  • Site not named

    Houston, Texas

  • Site not named

    Irving, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Southlake, Texas

  • Site not named

    Charlottesville, Virginia

  • Site not named

    Chesapeake, Virginia

  • Site not named

    Norfolk, Virginia

  • Site not named

    Richmond, Virginia

  • Site not named

    Seattle, Washington

  • Site not named

    Wauwatosa, Wisconsin

  • Site not named

    Footscray, Australia

  • Site not named

    Herston, Australia

  • Site not named

    Malvern, Australia

  • Site not named

    Melbourne, Australia

  • Site not named

    Ghent, Belgium

  • Site not named

    Leuven, Belgium

  • Site not named

    Mouscron, Belgium

Showing 40 of 87 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.